Artículo Aceptado para su pre-publicación / Article Accepted for pre-publication

Título / Title:
Neuropatía trigeminal traumática dolorosa; diagnóstico y tratamiento: a propósito de dos casos / Painful traumatic trigeminal neurpathy; diagnosis and treatment: about two clinical cases

Autores / Authors:
Christian Droguett Tidy, Jorge Lolas Millard, Constanza Labbé Martínez

DOI: 10.20986/recom.2021.1226/2020

Instrucciones de citación para el artículo / Citation instructions for the article:
NEUROPATÍA TRIGEMINAL TRAUMÁTICA DOLOROSA; DIAGNÓSTICO Y TRATAMIENTO: A PROPÓSITO DE DOS CASOS

PAINFUL TRAUMATIC TRIGEMINAL NEUROPATHY; DIAGNOSIS AND TREATMENT: ABOUT TWO CLINICAL CASES

Christian Droguett Tidy¹, Jorge Lolas Millard² y Constanza Labbé Martínez²

¹Department of Oral and Maxillofacial Surgery. Hospital del Trabajador. Oral and Maxillofacial Surgeon. Specialist in Pain Management. Faculty of Medicine. Universidad de Chile. Santiago, Chile. ²Department of Oral and Maxillofacial Surgery, Universidad de los Andes, Santiago, Chile

CORRESPONDENCE:
Christian Droguett Tidy
drdroguett@gmail.com

Recibido: 17-11-2020
Aceptado: 27-03-2021

RESUMEN

El dolor neuropático es originado como consecuencia directa de una lesión o enfermedad que afecta al sistema somatosensorial, lo cual es una condición crónica, debilitante, que afecta a un número significativo de pacientes. Las causas de dolor neuropático son diversas y el trauma es una de ellas. En este artículo se revisa la neuropatía trigeminal traumática dolorosa (PTTN). Se presentan dos casos clínicos. La primera es una mujer de 43 años con PTTN que fue diagnosticada nueve meses después de la reducción y osteosíntesis de una fractura cigomatomaxilar izquierda. El segundo caso corresponde a un varón de 62 años que consultó con una PTTN suborbitaria izquierda también tras una fractura cigomatomaxilar y su cirugía de reducción y osteosíntesis. En el primer caso clínico la paciente logró una reducción de un 70 %
de su sintomatología a los 6 meses de tratamiento mediante terapia farmacológica multimodal con pregabalina, carbamazepina y amitriptilina. El segundo paciente logró una resolución completa del dolor con carbamazepina, amitriptilina y parches de lidocaína, después de 2 meses. La terapia mediante esquema analgésico multimodal proporciona un pronóstico favorable, sin embargo, lograr una resolución total del dolor del paciente es un objetivo difícil de lograr, y una reducción significativa del 30 % o más en la EVA del paciente se considera un éxito de la efectividad de la terapia.

**Palabras clave:** Dolor neuropático, neuropatía trigeminal traumática dolorosa, trauma maxilofacial.

**ABSTRACT**

Neuropathic pain is originated as a direct consequence of an injury or disease that affects the somatosensory system, which is a chronic, debilitating condition that affects a significant number of patients. The causes of neuropathic pain are diverse, and trauma is one of them. In this article the Painful Traumatic Trigeminal Neuropathy (PTTN) is reviewed. Two clinical cases are presented. The first is a 43-year-old female with PTTN, who was diagnosed nine months after reduction and osteosynthesis of a left zygomatomaxillary fracture. The second case corresponds to a 62-year-old male who presented with a left suborbital PTTN also after a zygomatomaxillary fracture and its reduction and osteosynthesis surgery. In the first case, the patient achieved a 70 % of reduction in pain after 6 months of treatment using multimodal analgesia with pregabalin, carbamazepine and amitriptyline. The second patient achieved complete resolution of pain with multimodal therapy using carbamazepine, amitriptyline, and lidocaine patches after two months of treatment. Therapy through multimodal analgesic scheme provides a favorable prognosis, however achieving a total resolution of the patient’s pain is a difficult objective to achieve, and a significant reduction of 30% or more in the patient’s VAS is considered a success of the effectiveness of the therapy.
Key Words: Neuropathic pain, traumatic painful trigeminal neuropathy, maxillofacial trauma.

INTRODUCTION

Neuropathic pain can be caused by damage produced at any point in the nociceptive pathway, from the nociceptors to the cortical neurons of the brain\(^1\). Depending on the location of the damage, neuropathic pain can be classified as central or peripheral; according to its distribution as localized or diffuse; According to its etiology, it is classified as metabolic, secondary to ischemia, secondary to inflammation, paraneoplastic, neurodegenerative or traumatic\(^2,3\).

Painful Traumatic Trigeminal Neuropathy (PTTN) occurs in 3.3% of patients with trigeminal nerve injury. In patients with fractures of the zygomatic-maxillary complex, anesthesia or hypoesthesia is frequently observed at examination of territory corresponding to the innervation of infraorbital nerve. However, the development of persistent neuropathic pain occurs only in 3.3% of cases\(^1,2\).

Injury to a nerve delivers negative symptoms in an early stage such as anesthesia, hypoesthesia, or hypoalgesia. Later, it presents positive symptoms such as formication paresthesia, which corresponds to abnormal activity of A\(\beta\) fibers, and pain. The latter can be spontaneous or provoked, which can be of a burning nature, which suggests discharges of type C nociceptors, or lancinating, which suggests ectopic discharges originating in the axon of the A delta fiber\(^1,3\).

PTTN, unlike essential trigeminal neuralgia, usually presents as a persistent pain although it may have paroxysmal attacks on a painful basis; it is normally of a burning nature, although it may also have a lancinating component, and reaches a moderate to severe intensity\(^3\). Patients usually complain of swelling, heat or cold, and erythema in the area that hurts\(^4,5\). It shares other characteristic of all neuropathic pain, such as having a strict distribution to the affected dermatome and presenting allodynia and/or hyperalgesia.

According to the International Headache Society there are the following diagnostic criteria for PTTN:

1. Unilateral facial and/or oral pain that meets criterion 3.
2. History of identifiable trauma to the trigeminal nerve, with positive and/or negative clinical signs, these evidences of trigeminal nerve dysfunction.

3. Causality is demonstrated by the following two criteria:
   a) The pain follows the same distribution of the affected trigeminal nerve branch.
   b) The pain occurs between the third and sixth month after the trauma.

4. Absence of explanation for another diagnosis.

The management of neuropathic pain should be early and multimodal in nature, considering all therapeutic alternatives, both pharmacological and non-pharmacological.

The management of PTTN generally follows the recommendations for peripheral neuropathic pain, where membrane stabilizers and tricyclic antidepressants are the main drugs (Tables II, III).

A small number of patients may have very little or no response to pharmacological treatment and neurosurgical procedures appear as an alternative to this group of patients. These include radiofrequency rhizotomy, stereotaxic radiosurgery, open section of trigeminal nerve roots, and deep cerebral or cortical electrostimulation, but reports have shown disparate results for different conditions of neuropathic and non-neuropathic pain of the face.

CASE REPORTS

First case of a 43-year-old female (Figure 1.A) patient with a left zygomatic fracture, for which she underwent surgery for reduction and osteosynthesis. Nine months later, the patient consulted for pain assessed according to the visual-analog-scale (VAS) as 8 on the left side of the face, which described it as lancinating in the skin of the left genial region and the left side of the upper lip. At the touch of the area she reported 10 in VAS, and hypoesthesia of the left suborbital skin, left side of the upper dentoalveolar region. The finding of mechanical allodynia manifested by touch of the innervation territory corresponding to the left infraorbital nerve was evident.

The postoperative control image (Figure 1.B) showed a single osteosynthesis plate located in the zygomaticoalveolar-buttres on the same side. Was diagnosed as a PTTN that affected the
left suborbital nerve. With this, treatment with pregabalin was started with an initial dose of 75mg/day, after two weeks was has decrease in the severity of pain of 2 points in VAS was achieved, the dose was increased to 75 mg every 12 hours and carbamazepine 200mg per day was added to take as a single intake at the end of the day. After one month, the patient experienced pain relief that reached 50 % reduction in the value of VAS. Five months later a pain relief of 50 % was maintained but had isolated episodes of increased pain severity which maintained its characteristics. It was decided to add amitriptyline in doses of 12.5 mg per day. At the seventh month after the start of the therapy, the patient reported relief of the severity of the pain giving a 2 in VAS, which meant an improvement of 70 %.

The second clinical case corresponds to a 62-year-old male patient (Figure 2.A), who suffered an accident which resulted in a left side maxillary-zygoma fracture. He underwent surgery in another maxillofacial-surgery service, and three months later he began with a persistent lancinating sub-eyelid pain on the same side as the fracture, which reached a 5 in VAS and reached 9 with touch of the area or with movements of facial mimic muscles. Also had anesthesia in the same area of the pain that was present since the accident. On examination, the patient had alldynia to the touch of the left sub-palpebral territory, left nasal wing, and anterior area on the left side of the maxilla.

The CT scan (Figure 2.B) showed an operated left side zygomatomaxillary fracture, with osteosynthesis installed in the left frontozygomatic suture, infraorbital rim, zygomatomaxillary buttres and a mesh that covered the left infraorbital hole.

Given the described disposition of the mesh, it made suspect a possible compression of the suborbital nerve, so it was decided to remove it. At the surgery, the compression exerted on the affected nerve was verified. The patient was treated with pregabalin at a dose of 75 mg every 12 hours and lidocaine patches to be used 1 every 24 hours in the affected territory. One month after starting this treatment, the patient evolved favorably, reporting a VAS assessment of 4. Considering it still compromised the quality of life of the patient, amitriptyline was added in a single daily dose of 25 mg/day, after which, evolving favorably after one month reporting complete pain relief, assessing it according to VAS as 0.
DISCUSSION

The low incidence of neuropathic pain in these cases has been explained because of the trigeminal nerve experiencing markedly lower ectopic discharges compared to other peripheral nerves\(^{10}\). As pathophysiological considerations for neuropathic pain in the cases described, we can explain its occurrence through the formation of a neuroma or areas of demyelination in the suborbital nerve, given the bone displacement caused by the fracture.

We could argue that the best treatment is the prevention of neuropathic sequelae after trauma. This means that the indication for surgery should be considered promptly after having suffered the accident in maxillofacial fractures that compromise any branch of the trigeminal nerve, which at first will manifest with a negative neurological clinical sign (anesthesia, hypoesthesia or hypoalgesia), although the bone displacement is less, trying to achieve an anatomical reduction. This give a favorable anatomical territory to allow or provide an opportunity for a repair of the affected nervous trunk to occur, thus avoiding areas of demyelination or the formation of a neuroma.

The treatment of this condition must be done with drugs of first line or in combination with others of second or third line, always considering the strategy of \textit{multimodal analgesia} because of its effectiveness in pain control with lower incidence of side effects. The consequences in the quality of life of the patients who suffer PTTN can be devastating, given this, it’s essential that the maxillofacial surgery teams be trained in the diagnosis and treatment of this type of condition, in order to achieve timely and effective treatment.

REFERENCES


Table I. First-line drugs for the treatment of PTTN in the maxillofacial territory.

<table>
<thead>
<tr>
<th>First-line of treatment</th>
<th>Subclass</th>
<th>Mechanism of action</th>
<th>Recommended drug</th>
<th>Use in neuropathic pain</th>
<th>Dosage in PTTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticonvulsivants</td>
<td>GABA derivatives</td>
<td>Membrane stabilizers decreasing excitatory transmission over α2δ Subunit of Ca^{2+} Channel Voltage Dependent</td>
<td>Gabapentin</td>
<td>Relief allodynia, hyperalgesia, burning, lancinating pain</td>
<td>1800 to 3600 mg/day (3 doses)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Initial dose: 600 - 800 mg every 8 hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Start of action: 2 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maximum effect: 2 weeks post therapeutic dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Toxicity: drowsiness, dizziness, ataxia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interactions: Minimal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300 to 600 mg/day (2 or 3 doses)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pregabalin</td>
<td>Same effects as gabapentin in neuropathic pain. Adds anxiety effect Immediate analgesia</td>
<td>Initial dose: 75 to 150 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Start of action: 2 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maximum effect: 2 weeks post therapeutic dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Toxicity: drowsiness, dizziness, ataxia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interactions: Minimal</td>
</tr>
</tbody>
</table>
### Antidepressants

- **Tricyclic Antidepressants**
  - Mixed and variable blocking
  - Monoaminergic effect: Inhibition of serotonin and norepinephrine reuptake in synapses of the nociceptive pathway
  - Glutamatergic effect: Alters glutamate binding to NMDA receptors
  - Indirect effect on opioid receptors through monoaminergic neurons and inhibition of adenosine reuptake at synapses

**Amitriptylin**
- Relief of chronic pain by central and peripheral mechanisms
- Treatment of neuropathic pain requires lower doses than antidepressant treatment
- Sedative effect
- Effective in the relief of post-herpetic neuralgia and painful neuropathy secondary to diabetes
- Less effective action in neuropathy due to HIV and spinal cord injury
- Not effective in neuropathy due to cancer
- 12.5 to 75 mg/day (1 dose per day)
- Starting dose: 12.5 to 25 mg/day
- Adjust 1 time a month
- Onset of action: 2 weeks
- Maximum effect: 4 weeks
- Toxicity: Anticholinergic effects (dry mouth, constipation, urinary retention), blocking effects, sedation, weight gain, arrhythmias and seizures before overdose
- Interactions: CYP inducers and inhibitors

### Local anesthetics

- **Amides**
  - Na\(^+\) channel block in action potential
  - Slows down and blocks action potential from peripheral afferents

**Lidocaine**
- Lidocaína tópica: Alivio de alodinia y neuralgia post herpética desde aferencias.
- Útil en tratamiento inicial hasta lograr dosis efectiva multimodal
- Patches 5 % (700 mg in aqueous adhesive base)
- 1 patch every 12 to 24 hours
- Toxicity: Minimal, mild skin reactions
- Low plasma levels
- Interactions: Class I antiarrhythmics, Hepatic metabolism
## Table II. Second-line drugs for the treatment of PTTN in the maxillofacial territory.

<table>
<thead>
<tr>
<th>Second-line of treatment</th>
<th>Subclass</th>
<th>Mechanism of action</th>
<th>Recommended drug</th>
<th>Use in neuropathic pain</th>
<th>Dosage in PTTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidepressants</td>
<td>Selective serotonin-noradrenaline reuptake inhibitors (SNRIs)</td>
<td>Moderately selective blocking of serotonin and norepinephrine</td>
<td>Duloxetine</td>
<td>Chronic pain relief, Fibromyalgia treatment, Second line for neuropathic pain management, Greater tolerance than tricyclic antidepressants (they lack antihistamine, alpha adrenergic blocker and anticholinergic effects)</td>
<td>Duloxetine: 30 mg/day first week until reaching 60 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Venlafaxine: 75 to 225 mg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Start 37.5 mg/day first week until reaching 75 mg/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Onset of action: 2-4 weeks, Maximum effect: 4 weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Toxicity: Anticholinergic effects, risk of glaucoma and liver failure (duloxetine), sedation, hypertension (venlafaxine)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interactions: some inhibition of CYP 2D6 (Duloxetine, desvenlafaxine)</td>
<td></td>
</tr>
<tr>
<td>Opioids</td>
<td>Weak agonist opioid (μ)</td>
<td>Mixed effect: Weak μ agonist, moderate serotonin reuptake inhibitor and weak norepinephrine transporter inhibitor</td>
<td>Tramadol</td>
<td>Analgésico para dolor moderado, Adyuvante de opioides en síndromes de dolor crónico, Analgesia inmediata adyuvante en tratamiento multimodal de primera línea hasta efecto farmacológico óptimo, Efecto en dolor neuropático, polineuropatías, neuralgia post herpética y dolor neuropático secundario a diabetes mellitus, En caso de nauseas complementar con anihemético</td>
<td>50 to 400 mg/day (3 doses), Starting dose: 50-100 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Toxicity: Seizures, dizziness, constipation, nausea, vomiting, risk of serotonin syndrome, Risk of abuse, twenty</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interactions: Risk of serotonin syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Strong opioids</td>
<td>Strong agonists of μ receptor, affinity variable by δ and κ receptors</td>
<td>Morphine, Methadone, Fentanyl</td>
<td>Intense pain, Adjunct in general anesthesia and sedation (fentanyl, remifentanil, morphine), Pulmonary edema (morphine only), Maintenance in programs rehabilitation (methadone only), In chronic neuropathic pain, a weak μ agonist is preferable</td>
<td>Tithable dose according to case, Immediate effect, Some available in long-lasting transdermal patches, Duration: 1-4 h except methadone, 4-6 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Toxicity: respiratory depression, severe constipation, addiction liability, seizures, urinary retention, nausea / vomiting, delirium</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interactions: Sedative hypnotics (respiratory depression), Antipsychotic agents (increased sedation and cardiovascular effects), monoamine oxidase inhibitors (hyperpyrexia coma and arterial hypertension)</td>
<td></td>
</tr>
<tr>
<td>Third-line of treatment</td>
<td>Subclass</td>
<td>Mechanism of action</td>
<td>Recommended drug</td>
<td>Use in neuropathic pain</td>
<td>Dosage in PTTN</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Na(^+) channel blockers</td>
<td>Na(^+) channel blockers and inhibition of glutamate release by neurons of the central nervous system. twenty Rapid oral absorption, maximum levels in 4-5 hours</td>
<td>Carbamazepine</td>
<td>Use in tonic-clonic crisis focal and focal bilateral, use in neuropathic pain. First level of evidence for essential trigeminal neuralgia, but its efficacy for PTTN is disputed with limited results in some studies.</td>
<td>800-1200 mg/day; the maximum dose. Gradual increase. For neuropathic pain 100 to 200mg every 12 hours is recommended. Toxicity: nausea, diplopia, ataxia, hyponatremia, headache. Interactions: phenytoin, valproic acid, fluoxetine, verapamil, antibiotics, macrolides, isoniazid, propoxyphene, danazol, phenobarbital, primidone, among others.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Oxcarbazepine</td>
<td>Similar effects and mechanism of action as carbamazepine.</td>
<td>300 mg/day to 600mg every 12 hours. The clinical dose of oxcarbazepine may need to be 50 % higher than that of carbamazepine. Fewer interactions reported.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lamotrigine</td>
<td>Use in focal seizures, generalized tonic-clonic seizures, absence seizures, other generalized seizures; depression Bipolar. Its effectiveness in controlled trials was poor and its potential skin toxicity gives it a third level of Choice for the management of neuropathic pain.</td>
<td>100 to 300 mg/day. Initial dose is 25 mg/day, and increases to 50 mg/day after 2 weeks; subsequently, the degree can advance by 50 mg/day every 1-2 weeks up to a regular maintenance dose. 225-375 mg / d (in two divided doses) In patients receiving valproate, the starting dose of lamotrigine should be reduced to 12.5-25 mg every other day, with increases of 25-50 mg/day every 2 weeks as needed at a usual maintenance dose of 100-200 mg/day. Toxicity: dizziness, headache, diplopia, rash. Interactions: valproic acid, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, primidone, succinimides, sertraline, topiramate.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Valproic acid</td>
<td>Use tonic-clonic seizures widespread crisis partial, absence seizures, myoclonic seizures, other generalized seizures; migraine prophylaxis. Its mechanism of action is still unknown. No greater effectiveness than placebo has been found in some poor quality studies.</td>
<td>15 mg/kg with one titration slow until therapeutic dose. Doses of 25-30 mg/kg/d. Toxicity: nausea, tremor, weight gain, loss of hair, teratogenic, hepatotoxic. Interactions: phenobarbital, phenytoin, carbamazepine, lamotrigine, felbamate, rifampin, ethosuximide, primidone.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Topiramate</td>
<td>Focal crisis, crisis generalized primaries, Lennox syndrome- Gastaut; prophylaxis of migraine</td>
<td>100 mg/day. Initial dose 25-50 mg / day and gradual increase. Toxicity: drowsiness, cognitive slowing confusion, paresthesias. Interactions: phenytoin, carbamazepine, contraceptives oral, lamotrigine, lithium.</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Selective serotonin reuptake inhibitors (SSRIs)</td>
<td>Highly selective blocking of the serotonin transporter little effect on the norepinephrine transporter. Acute increase in serotonergic synaptic activity slower changes in various signaling pathways and neurotrophic activity</td>
<td>Paroxetine</td>
<td>Major depression, anxiety disorders • panic disorder • obsessive-compulsive disorder • disorder posttraumatic stress • vasomotor symptoms perimenopausal • eating disorder Third-line use in neuropathic pain.¹³</td>
<td>Variable dose Toxicity: sexual dysfunction, risk of serotonin syndrome with iMAO Interactions: some inhibition of CYPs (fluoxetine 2D6, 3A4, fluvoxamine 1A2, paroxetine 2D6)</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td>Tetracylic, monocyclic</td>
<td>Increased activity of norepinephrine and dopamine (bupropion) • NET&gt; SSRI inhibition (amoxapine, maprotiline) Increased release norepinephrine, 5-HT (mirtazapine) Presynaptic release of catecholamines, but no effect on 5-HT (bupropion) • the Amoxapine and Maprotiline resemble tricyclics</td>
<td>Bupropion</td>
<td>Third line use</td>
<td>Variable dose Extensive liver metabolism. Toxicity: lowers the seizure threshold (amoxapine, bupropion). Interactions: CYP2D6 inhibitor</td>
</tr>
<tr>
<td>Other</td>
<td>Neurotoxins (Capsaicin)</td>
<td>Interaction with the vanilloid receptor VR1 of type C sensory fibers activate the vanilloid receptors of the skin and generate their you see pain, stinging and later analgesia This receptor is a non-selective cation channel, with a high permeability for calcium¹² Promotes the release and inhibits the biosynthesis and axonal transport of substance P, which leads to a depletion of substance P in the central and peripheral nervous system produces reversible desensitization of C-fiber sensory endings. It can cause a degeneration of the nerve fibers of the epidermis.</td>
<td>Capsaicin</td>
<td>There is moderate-quality evidence that high-concentration (8%) capsaicin patches can provide moderate pain relief, or better, to a minority of patients with postherpetic neuralgia, and very low-quality evidence that they benefit patients with HIV neuralgia and diabetic peripheral neuropathy. Third line of treatment in neuropathic pain management¹⁵</td>
<td>Topical: 0.025-0.075 %, application every 6 to 8 hours in the affected area. 8 % high concentration patches. In 80 % of cases, there may be a burning or stinging sensation in the area of application, irritative erythema, dry skin</td>
</tr>
</tbody>
</table>
Figure 1. Case 1. A. 43-year-old female patient with a left maxillary-zygomatic fracture. B. Postoperative control CT-3D reconstruction.
Figure 2. Case 2. A. 62-year-old male patient with a left side maxillary-zygomatic fracture. B. CT-3D reconstruction showing an operated left side zygomatomaxillary fracture.